RxDoctor Payments Data

Kimberlee Curnyn, MD

Ophthalmology · Arlington Heights, ILNPI 1669575296

Payments from drug & device makers

$4,036in general payments, 2019–2025

Across 120 payments — averaging $33.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$588
  • Amgen$543
  • Alcon$494
  • AbbVie$482
  • Johnson & Johnson Surgical Vision, Inc.$406
  • Rxsight Inc$362
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$4,036100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,036 in reported general payments places this provider in the 75th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$385,721
Medicare patients
1,235
Services billed
3,888

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Phospholine IodideEchothiophate Iodide12$31,603
RestasisCyclosporine20$29,686
XiidraLifitegrast15$20,817
LumiganBimatoprost18$10,611
Cyclosporine15$10,221
Latanoprost368$5,315
VyzultaLatanoprostene Bunod14$5,148
ErythromycinErythromycin Base304$3,136
Brinzolamide13$1,485
Ketorolac Tromethamine43$1,386
Tobramycin-DexamethasoneTobramycin/Dexamethasone31$1,382
Travoprost12$1,136
Prednisolone Acetate25$977
Timolol Maleate87$648
Brimonidine Tartrate16$633

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$482$40,29838 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$588$25,96529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in Arlington Heights

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →